NICE Rejects Jevtana Because Of Cost, But Clears ALK Abello's Bee Sting Prophylaxis
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.'s cost regulator, NICE, rejects Sanofi's lauded prostate cancer therapy cabazitaxel because it considers it too expensive.
You may also be interested in...
NICE Rules Out Sanofi’s Jevtana On Grounds Of Cost Effectiveness
NICE has turned down Sanofi’s Jevtana for prostate cancer, raising fears in England of a new post-code lottery for cancer drugs and highlighting the different between Germany and England’s health technology assessments.
European HTA Round-Up: NICE Focuses On Cost Effectiveness, IQWiG On Clinical Benefit, But Convergence May Come
It is becoming increasingly clear that NICE and IQWiG have very different concerns on the reimbursement front, but it is only a matter of time before IQWiG gets its teeth into cost-benefit analyses
EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe
While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.